Ogilvy Medical responded to the poisoning of employees of its Hubei subsidiary.
On the morning of August 5, Ogilvy & Mather Medical Products Co., Ltd. (Ogilvy & Mather Medical, 002950) announced that recently, its subsidiary Ogilvy & Mather (Jingmen) Medical Products Co., Ltd. (“Jingmen Ogilvy & Mather”) has some The employee experienced physical symptoms and was diagnosed as a poisoning incident. After preliminary judgment, the suspected cause of poisoning was caused by inhaling tetrachloroethane released from PET glue.
According to the announcement, the glue is only used for products packaged in PET plastic hard boxes customized by Jingmen Ogilvy & Mather. The production process involved is the sealing process of PET plastic hard boxes, and the production process involved is limited to Jingmen Ogilvy & Mather. , does not involve other products and other production processes produced by Ogilvy Medical. As of the time of the announcement, after multiple rounds of health tests on people with a history of contact with the workshop, a total of 43 people with abnormal indicators were treated in the hospital, and one employee died of acute myocardial infarction during the treatment process. , the rest of the staff are still under treatment.
Ogilvy Medical said that the company is cooperating with local relevant departments to investigate the incident, and the specific cause of the incident and related responsibilities need to be further verified. The PET plastic hard box packaging process involved in the incident was the first to be introduced into production recently, and the contract amount involved was about 2.2 million yuan. After preliminary judgment, the incident will not have a significant impact on the company’s production and operation for the time being.
According to the official website and 2021 annual report, Ogilvy Medical was founded in Hong Kong in 1997 and listed on the Shenzhen Stock Exchange in March 2019. Its main business is the research and development of medical consumables and disposable medical devices, infection protection products, and home care products. It is the only manufacturing enterprise in the whole industry chain that realizes integrated, large-scale and intelligent production of medical dressings, infection protection products and medical non-woven products in the world in terms of production and sales. The core business focuses on medical low-value consumables products. Currently, there are three product segments: wound care, surgical consumables and infection protection. Products are exported to 5 continents, and we have established long-term cooperative relationships with more than 100 international well-known brands.
According to the 2021 annual report, Ogilvy Medical has a total of 4,964 employees, including 3,881 production personnel, accounting for over 78% of the total number of employees. The poisoning incident involved Ogilvy & Mather (Jingmen) Medical Supplies Co., Ltd., a first-tier subsidiary directly invested by Ogilvy Medical, whose business nature is the production and sales of medical dressings.
The 2021 annual report shows that Ogilvy Medical’s total operating income was 2.926 billion yuan, a year-on-year decrease of 23.7%; the net profit attributable to shareholders of listed companies was 431 million yuan, a year-on-year decrease of 62.75%. Ogilvy Medical said that the decline in revenue and profit was mainly due to the fall in the price of anti-epidemic materials. According to the first quarterly report of this year, revenue was 993 million yuan, a year-on-year increase of 21.02%; net profit attributable to shareholders of listed companies was 158 million yuan, a year-on-year increase of 35.61%; net profit attributable to shareholders of listed companies was 139 million yuan, a year-on-year increase of 41.87%. The company expects to disclose its 2022 interim report on August 30.
The first quarterly report also showed that the total number of ordinary shareholders at the end of the reporting period was 54,856. As of the close on August 4, Ogilvy Medical closed up 1.82% at 12.87 yuan, with a market value of 8.15 billion yuan.